Women with non-small cell lung cancers live longer than men
Women with non-small cell lung cancers live longer than men

Source: Loyola University Health System

News • Research

Non-small cell lung cancer: women live longer than men

Women diagnosed with non-small cell lung cancers (NSCLC) live longer than their male counterparts, according to results of a SWOG study presented by Loyola Medicine researcher Kathy Albain, MD, at the International Association for the Study of Lung Cancer's 19th World Conference on Lung Cancer in Toronto.

Dr. Albain led the international study, S0424, for SWOG, the cancer clinical trials group that is part of the National Cancer Institute's National Clinical Trials Network, the nation's oldest and largest publicly-funded cancer research network. Dr. Albain and her SWOG team studied 981 patients newly diagnosed with stage I, II or III NSCLC. Non-small cell lung cancers account for about 80 to 85 percent of all lung cancers.

Researchers grouped patients into four groups based on sex and smoking history. Then, they analyzed data on cancer stage, patients' tumor type and mutations, hormonal influences, treatment plans and survival rates. Patients were followed for five years, or until their deaths, in order to determine overall survival, or how long they lived after enrolling in the trial.

Prospective trial

The study is the first prospective trial of this scope for NSCLC, designed specifically to follow survival outcomes. It represents collaboration across the clinical trials network, and included researchers from Canada and Japan.

Regardless of smoking history or any other factor, women in S0424 had significantly better overall survival (OS) rates compared to men. The analysis found that female never-smokers (FNS) and female ever-smokers (FES) had significantly better OS compared to male never-smokers (MNS) and male ever-smokers (MES). Five-year estimates reported overall survival at 73 percent for FNS, 69 percent for FES, 58 percent for MNS and 52 percent for MES. Women lived longer, even when adjustments were made for the medical care they received, their smoking history, hormonal factors, or the presence of mutations in their tumors common to NSCLC types.

"Females with NSCLC survive better, even when we control for every factor that might influence survival in NSCLC, including tobacco and other exposures, lifestyle factors, disease stage, treatment, tumor biology and hormonal factors," Dr. Albain said. "Additional study is needed to further investigate favorable female survival in this population and our large clinical trials need to be equally balanced for females."

Source: Loyola University Health System

02.10.2018

Read all latest stories

Related articles

Photo

Report • Cancer mortality study

Does ethnicity affect brain tumour survival?

New research has pinpointed ethnicity as a potential factor in brain tumour survival. A UK study showed that white British people who have been diagnosed with a malignant primary brain tumour appear…

Photo

News • Software solution

Using AI to match cancer patients to early phase clinical trials

Cancer informatics and digital pathology provider Inspirata announced that King’s Health Partners ECMC and Guy’s and St Thomas’ NHS Foundation Trust will pilot its Trial Navigator software as…

Photo

News • Oncology early detection tool

Blood test for 50+ types of cancer promising for screening

Final results from a study of a blood test that can detect more than 50 types of cancer have shown that it is accurate enough to be rolled out as a multi-cancer screening test among people at higher…

Related products

Canon – Alphenix 4D CT

Multi-Modality Suites

Canon – Alphenix 4D CT

Canon Medical Systems Europe B.V.
Canon - Aquilion Exceed LB

Oncology CT

Canon - Aquilion Exceed LB

Canon Medical Systems Europe B.V.
Canon – Aquilion LB

Oncology CT

Canon – Aquilion LB

Canon Medical Systems Europe B.V.
Canon – Vitrea Advanced Visualization

Reading

Canon – Vitrea Advanced Visualization

Canon Medical Systems Europe B.V.
Sarstedt – Low DNA Binding Micro Tubes

Research Use Only

Sarstedt – Low DNA Binding Micro Tubes

SARSTEDT AG & CO. KG
Subscribe to Newsletter